A prospective, controlled study. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Aldosterone secretion in steroid-treated patients with adrenal suppression.
Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Erratum in: JAMA. Plasma cortisol is often decreased in patients treated in an intensive care unit.
Intensive Care Med. Oelkers W. Adrenal insufficiency. Hyperreninemic hypoaldosteronism in the critically ill: a new entity. The dissociation of renin and aldosterone during critical illness. Balk RA. Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations. Crit Care Clin.
The pathogenesis of vasodilatory shock. Dellinger RP. Cardiovascular management of septic shock. The pathophysiology and treatment of sepsis. Reducing mortality in sepsis: new directions. Crit Care. Epub Dec 5. Corticosteroid supplementation for adrenal insufficiency. Corticosteroid therapy in severe illness. Adrenal insufficiency in the critically ill: a new look at an old problem. Annane D.
Corticosteroids for septic shock. Precipitation of diabetes mellitus. In patients with diabetes, increased dosages of insulin or oral hypoglycemic agent and changes in diet should be expected. Use with extreme caution in patients with recent myocardial infarction because of an apparent association with left ventricular free-wall rupture. Use with caution in patients with thromboembolic disorders because of reports of rare increased blood coagulability.
CHF exacerbation. Prolonged use may result in increased intraocular pressure or damaged ocular nerve. Use in patients with ocular herpes simplex may cause corneal perforation. Muscle pain or weakness, muscle wasting, pathologic long bone or vertebral compression fractures, atrophy of protein matrix of bone, aseptic necrosis of femoral or humeral heads.
Use with caution in patients prone to development of osteoporosis; risk versus benefit should be reassessed if osteoporosis develops; elderly, debilitated or poorly nourished patients may be more prone to these effects.
Supplementation with calcium, 1, mg per day, and vitamin D, IU per day, is recommended. Headache, vertigo, seizures, increased motor activity, insomnia, mood changes, psychosis. Use with caution in patients with convulsive or psychiatric disorders. Use may aggravate preexisting psychiatric conditions. Steroid-induced psychosis is dose-related, occurs within 15 to 30 days of therapy and is treatable if steroid therapy must be continued.
Pseudotumor cerebri reported during withdrawal. Ecchymoses due to easy bruisability should be restricted to exposed, potentially traumatized extremities, when associated with steroid use. Contraindicated in patients with systemic fungal infections except to control drug reactions associated with amphotericin B [Fungizone] therapy.
Do not use live virus vaccinations during therapy. Reactions to skin tests may be suppressed. Information from references 1 through 4. The dosage range for steroids is wide, and patient response is variable. A low or maintenance dosage is approximately 0. Short-term, low-dose steroid therapy rarely results in any of the adverse effects listed in Table 2.
In long-term therapy, alternate-day administration should be considered. Some disease states, however, such as temporal arteritis and systemic lupus erythematosus, may not be adequately controlled with alternate-day therapy. Doubling the dosage and administering the drug every other day in the morning more closely mimics the endogenous corticosteroid circadian rhythm.
This form of administration enables the patient to experience the therapeutic effects while side effects are minimized. To allow recovery of normal pituitary-adrenal responsiveness to secretion of endogenous corticosteroid without exacerbating the underlying disease state. In most patients, endogenous corticosteroid secretions are equivalent to 5 to 7. Tapering the dosage over 2 months or more may be necessary for patients on prolonged treatment more than 1 year.
Depending on dosage, duration of therapy and risk of systemic disease, decrease dosage by the equivalent of 2. Then perform a challenge to determine the extent of HPA axis recovery. Depending on the results and patient's symptoms, therapy may be discontinued or a slower taper considered.
Headache, dizziness, fainting, fatigue, lethargy, myalgia, joint pain, dyspnea, orthostatic hypotension, nausea, vomiting, anorexia, weight loss, fever, hypoglycemia, desquamation of skin. If symptoms do not subside when steroid dosage is adjusted, other causes must be considered. Information from references 1 through 3 , and 5. Viral croup is a common childhood disease. In fact, it is the most common form of upper airway obstruction in children six months to six years of age.
Corticosteroids have been studied in the management of croup for the past 30 years, but their use in this condition is controversial. The use of steroids in children with croup is associated with significant clinical improvement at about 12 hours post-treatment and results in less endotracheal intubation.
Most current research focuses on outpatient use of corticosteroids in the treatment of moderate and severe croup. Some authors have found that routine use of steroids reduces the need for hospitalization. Although budenoside is well tolerated with minimal side effects because of limited systemic availability, it is not yet available for use in the United States except in a nasal form. A single intramuscular injection of 0. Therefore, intramuscular corticosteroid treatment should be considered in patients with moderate croup before discharge from the emergency department when outpatient therapy is entertained.
Pneumocystis carinii pneumonia PCP is a leading cause of morbidity and mortality in patients infected with human immunodeficiency virus HIV. This clinically significant complication of HIV infection occurs in 60 to 80 percent of patients with acquired immunodeficiency syndrome not receiving prophylaxis 14 and causes death in approximately 25 percent of its victims.
Since the late s, adjunctive treatment with corticosteroids has been documented in case reports and research studies with favorable clinical results, and it is currently endorsed by the National Institutes of Health as a standard therapy. Documented benefits of corticosteroid therapy in patients with PCP include reduced morbidity and mortality, decreased need for mechanical ventilation assistance and a reduced long-term decline in pulmonary function or exercise tolerance.
Progression of other opportunistic infections associated with HIV infection as a result of the immunosuppressive effects of corticosteroids is a risk that must be considered.
While some studies report only minor complications associated with steroid therapy, such as reactivation of localized herpetic lesions, 18 others have reported an increased incidence of infection and cancer. Based on the benefits and risks of adjunctive corticosteroid therapy, the current recommendations are not intended for all patients but only for those with confirmed or suspected HIV and PCP infection who are at high risk of respiratory failure and death.
Patients at risk include those with an arterial oxygen pressure of less than 70 mm Hg or an arterial-alveolar gradient of more than 35 mm Hg. The recommended dosing regimen is oral prednisone, 40 mg twice daily for five days, then 40 mg once daily for five days, then 20 mg daily for the duration of the anti-pneumocystis therapy. Methylprednisolone, given at 75 percent of the oral prednisone dosage, can be substituted if parenteral therapy is necessary. A confirmatory diagnosis of PCP and HIV infection should be obtained, and other diseases, such as tuberculosis and cryptococcosis, should be ruled out before steroid therapy is begun.
Further investigation is required to determine the appropriate use and benefits of steroid therapy when the patient has concomitant life-threatening infections and when the patient has already received more than three days of anti-pneumocystis therapy and has developed significant hypoxia.
Hyperthyroidism is a common disease affecting around 2 percent of women and 0. The amount of benefit and the effect on patient outcome in this circumstance is not yet known. Graves' eye disease is treated by first normalizing the thyroid function and then administering diuretics and systemic glucocorticoids. Other causes of hyperthyroidism that may be treated with corticosteroids are subacute thyroiditis and thyroid storm. Hyperthyroid disease related to thyroiditis is usually mild and self-limited.
Beta blockers may be used to treat symptoms. In subacute thyroiditis, non-steroidal anti-inflammatory drugs or corticosteroids can be used to relieve thyroid pain and tenderness. Thyroid storm is a life-threatening condition of the hyperthyroid state.
Corticosteroids are used as adjuvant analgesics for pain in cancer patients and patients with neuropathic pain such as herpes zoster—related neuropathy, spinal cord compression and pain following oral surgery.
Prednisone, at a dosage of 7. Patients with nerve compression pain or pain resulting from increased intracranial pressure showed a better response when compared with patients with other pain syndromes.
Perioperative use of corticosteroids has been advocated to reduce pain and decrease edema and trismus following oral surgical procedures. The most significant improvement occurs in the treatment of postoperative edema.
Dosages of prednisone between 40 and 80 mg per day can be used. Maximal benefit has been achieved after third-molar extraction, although some benefit has been reported after other surgeries. Some evidence indicates that combining corticosteroids with acyclovir Zovirax will decrease the duration of zoster-associated pain. Systemic treatment with corticosteroids such as prednisone, at 40 mg per day for three weeks, decreases the proportion of patients affected by postherpetic neuralgia, especially pain occurring six to 12 weeks after onset.
Alcoholic hepatitis is a chronic, progressive and often fatal disease. Treatment has generally been supportive. Meta-analysis of studies from to supports the finding that patients with acute severe alcoholic hepatitis and hepatic encephalopathy, without gastrointestinal bleeding, benefit from a trial of corticosteroid therapy.
Further clinical trials were recommended to clarify the role of steroids in the treatment of alcoholic hepatitis. Bacterial meningitis is a serious disease that may result in death or permanent neurologic complications such as seizures, paralysis or sensorineural hearing loss.
These produce inflammatory components such as cytokines, which lead to meningeal inflammation and increased intracranial pressure. Studies show that potent corticosteroids, such as dexamethasone, combined with appropriate antibiotics reduce the risk of acquired sensorineural deafness and the incidence of other neurologic sequelae in meningitis caused by Haemophilus influenzae. The drug was administered in a dosage of 0. Corticosteroids may also be used in the treatment of tuberculous meningitis.
In one randomized, controlled study 55 involving 47 patients in India, dexamethasone was found to be useful as an adjunct treatment in cases of tuberculous meningitis, especially in patients with severe disease. A more recent randomized trial 56 using prednisone in children with tuberculous meningitis showed that prednisone in a dosage of 2 to 4 mg per kg per day for one month improved survival rate and intellectual outcome.
Table 4 57 lists other unlabeled uses of corticosteroids. Dexamethasone, 0. Methylprednisolone, given intravenously within 8 hours of injury, to improve neurologic function. Prednisolone, 0. Adapted with permission from Drug facts and comparisons. Louis: Facts and Comparisons, b.
Already a member or subscriber? Log in. Interested in AAFP membership? Learn more. Zoorob is a graduate of the American University of Beirut and completed residency training in family practice at Anderson S. Memorial Hospital. Chandler Medical Center, Lexington. Do not keep out-of-date or unwanted medicines. Take them to your local pharmacy which will dispose of them for you. Manufacturer's PIL, Fludrocortisone acetate 0. Dated June Hello everyoneI've been ill for so many years and went down the rabbit hole of every specialist there is to see.
This is my 3rd round out of 13 years of seeing an endocrinologist and next week I Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Egton Medical Information Systems Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy.
Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions. You must take fludrocortisone each day. In this article About fludrocortisone Before taking fludrocortisone How to take fludrocortisone Getting the most from your treatment Can fludrocortisone cause problems? How to store fludrocortisone Important information about all medicines. Fludrocortisone tablets In this article About fludrocortisone Before taking fludrocortisone How to take fludrocortisone Getting the most from your treatment Can fludrocortisone cause problems?
About fludrocortisone Type of medicine Corticosteroid Used for Replacement treatment in people with Addison's disease or following surgical removal of the adrenal glands Also called Fludrocortisone acetate Available as Tablets.
Common fludrocortisone side-effects What can I do if I experience this? Fluid retention causing swollen feet and ankles Whenever possible, sit with your feet up Tummy abdominal pain, feeling sick nausea or bloated, indigestion Stick to simple meals and avoid rich or spicy foods Muscle weakness or feeling tired If this happens, do not drive and do not use tools or machines until you feel better Mood or behavioural changes, especially at the beginning of treatment If you become confused, anxious, irritable, have trouble sleeping or start having worrying thoughts about harming yourself, speak with your doctor as soon as possible Increased appetite or weight gain, irregular periods in women If any of these become troublesome, speak with your doctor Long-term treatment may cause other unwanted effects If you have any symptoms which cause you concern, you should arrange to see your doctor for advice.
0コメント